Literature DB >> 10027007

Signal transduction by the receptor tyrosine kinase Ret.

D H van Weering1, J L Bos.   

Abstract

Ret is the receptor for glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN). Defects in this receptor underlie several genetic syndromes. The receptor is a transmembrane tyrosine kinase which transduces Ret-mediated signaling to a variety of signaling pathways, most notably the Ras signaling pathway and the phosphatidylinositol-3 kinase pathway. These pathways are activated through the interaction of adaptor proteins to tyrosine phosphorylated receptor. The ultimate biological effects, depending on the cell type, include morphological changes in the cytoskeleton, cell scattering, proliferation, and differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10027007     DOI: 10.1007/978-3-642-46870-4_18

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  15 in total

1.  Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Krishna M Sinha; Ling Li; Yue Lu; Gilbert J Cote; Steven I Sherman; Robert F Gagel
Journal:  Mol Cancer Res       Date:  2018-12-14       Impact factor: 5.852

2.  Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo.

Authors:  J T Erickson; T A Brosenitsch; D M Katz
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 3.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

4.  Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression.

Authors:  N A Shackel; P H McGuinness; C A Abbott; M D Gorrell; G W McCaughan
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

5.  Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.

Authors:  E de Graaff; S Srinivas; C Kilkenny; V D'Agati; B S Mankoo; F Costantini; V Pachnis
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

Review 6.  Drug Targets in Neurotrophin Signaling in the Central and Peripheral Nervous System.

Authors:  Mahendra Pratap Kashyap; Callie Roberts; Mohammad Waseem; Pradeep Tyagi
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

Review 7.  Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  J Mol Med (Berl)       Date:  2003-06-14       Impact factor: 4.599

8.  Pleiotrophin is a neurotrophic factor for spinal motor neurons.

Authors:  Ruifa Mi; Weiran Chen; Ahmet Höke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

9.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

10.  Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform.

Authors:  Adrianne Wong; Silvia Bogni; Pille Kotka; Esther de Graaff; Vivette D'Agati; Frank Costantini; Vassilis Pachnis
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.